ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
16.16
+0.60 (3.86%)
At close: Sep 18, 2025, 4:00 PM EDT
15.96
-0.20 (-1.24%)
After-hours: Sep 18, 2025, 4:41 PM EDT

ADMA Biologics Statistics

Total Valuation

ADMA Biologics has a market cap or net worth of $3.86 billion. The enterprise value is $3.81 billion.

Market Cap3.86B
Enterprise Value 3.81B

Important Dates

The next estimated earnings date is Thursday, November 6, 2025, after market close.

Earnings Date Nov 6, 2025
Ex-Dividend Date n/a

Share Statistics

ADMA Biologics has 238.63 million shares outstanding. The number of shares has increased by 5.91% in one year.

Current Share Class 238.63M
Shares Outstanding 238.63M
Shares Change (YoY) +5.91%
Shares Change (QoQ) +1.61%
Owned by Insiders (%) 1.95%
Owned by Institutions (%) 90.71%
Float 233.87M

Valuation Ratios

The trailing PE ratio is 19.12 and the forward PE ratio is 22.39.

PE Ratio 19.12
Forward PE 22.39
PS Ratio 7.77
Forward PS 6.58
PB Ratio 9.32
P/TBV Ratio 9.69
P/FCF Ratio 58.09
P/OCF Ratio 49.81
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 23.32, with an EV/FCF ratio of 57.99.

EV / Earnings 18.26
EV / Sales 8.04
EV / EBITDA 23.32
EV / EBIT 24.51
EV / FCF 57.99

Financial Position

The company has a current ratio of 5.33, with a Debt / Equity ratio of 0.21.

Current Ratio 5.33
Quick Ratio 2.67
Debt / Equity 0.21
Debt / EBITDA 0.51
Debt / FCF 1.27
Interest Coverage 15.28

Financial Efficiency

Return on equity (ROE) is 71.23% and return on invested capital (ROIC) is 23.96%.

Return on Equity (ROE) 71.23%
Return on Assets (ROA) 20.81%
Return on Invested Capital (ROIC) 23.96%
Return on Capital Employed (ROCE) 32.19%
Revenue Per Employee $692,225
Profits Per Employee $305,003
Employee Count685
Asset Turnover 1.01
Inventory Turnover 1.20

Taxes

Income Tax -63.92M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -13.63% in the last 52 weeks. The beta is 0.53, so ADMA Biologics's price volatility has been lower than the market average.

Beta (5Y) 0.53
52-Week Price Change -13.63%
50-Day Moving Average 17.30
200-Day Moving Average 18.42
Relative Strength Index (RSI) 44.07
Average Volume (20 Days) 3,103,990

Short Selling Information

The latest short interest is 14.98 million, so 6.28% of the outstanding shares have been sold short.

Short Interest 14.98M
Short Previous Month 14.96M
Short % of Shares Out 6.28%
Short % of Float 6.40%
Short Ratio (days to cover) 4.62

Income Statement

In the last 12 months, ADMA Biologics had revenue of $474.17 million and earned $208.93 million in profits. Earnings per share was $0.85.

Revenue474.17M
Gross Profit 251.32M
Operating Income 155.64M
Pretax Income n/a
Net Income 208.93M
EBITDA 163.55M
EBIT 155.64M
Earnings Per Share (EPS) $0.85
Full Income Statement

Balance Sheet

The company has $90.29 million in cash and $83.83 million in debt, giving a net cash position of $6.46 million or $0.03 per share.

Cash & Cash Equivalents 90.29M
Total Debt 83.83M
Net Cash 6.46M
Net Cash Per Share $0.03
Equity (Book Value) 398.33M
Book Value Per Share 1.67
Working Capital 324.62M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $76.71 million and capital expenditures -$10.94 million, giving a free cash flow of $65.77 million.

Operating Cash Flow 76.71M
Capital Expenditures -10.94M
Free Cash Flow 65.77M
FCF Per Share $0.28
Full Cash Flow Statement

Margins

Gross margin is 53.00%, with operating and profit margins of 32.82% and 44.06%.

Gross Margin 53.00%
Operating Margin 32.82%
Pretax Margin 30.58%
Profit Margin 44.06%
EBITDA Margin 34.49%
EBIT Margin 32.82%
FCF Margin 13.87%

Dividends & Yields

ADMA Biologics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -5.91%
Shareholder Yield -5.91%
Earnings Yield 5.47%
FCF Yield 1.72%

Analyst Forecast

The average price target for ADMA Biologics is $27.67, which is 71.23% higher than the current price. The consensus rating is "Strong Buy".

Price Target $27.67
Price Target Difference 71.23%
Analyst Consensus Strong Buy
Analyst Count 3
Revenue Growth Forecast (5Y) 22.72%
EPS Growth Forecast (5Y) 19.87%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

ADMA Biologics has an Altman Z-Score of 17.77 and a Piotroski F-Score of 6.

Altman Z-Score 17.77
Piotroski F-Score 6